$NVLX According to the American cancer Society, in the US

New Post Public Reply Private Reply Replies (0) Message Board

Mar 13, 2014 at 10:35 AM

$NVLX According to the American cancer Society, in the US alone, approximately 45,000 new cases of pancreatic cancer are expected to be diagnosed this year and about 38,000 people are predicted to die from the disease; it is the leading cause of cancer deaths in the US and worldwide. Often pancreatic cancer is not diagnosed until it has reached an advanced stage. By this time, the cancer cannot be removed surgically, is often resistant to radiation therapy or chemotherapy, and has spread (metastasized) to other organs in the body. Because of this, the average survival of patients with advanced, inoperable pancreatic cancer is given in terms of weeks or months, not years.Nuvilex’s pancreatic cancer treatment consists of the use of a proprietary cellulose-based live-cell encapsulation technology together with the long-known and widely used anticancer drug ifosfamide.In a Phase I/II open-label, prospective, single-arm clinical trial, the live-cell encapsulation/ifosfamide combination was used to treat patients with advanced, inoperable pancreatic cancer. Fifty-one patients were originally “screened” for the trial; of these, 17 were enrolled in the study. Other patients were excluded from enrollment for therapy because of previous chemotherapy, previous pancreatic surgery, poor overall health, unwillingness to participate, or death prior to the start of the trial. Of the 17 patients initially enrolled in the study, 14 were ultimately treated. Results obtained in the clinical trial were compared with historical data for gemcitabine and included: median survival time of 44 weeks (after diagnosis) with the cell encapsulation/ifosfamide treatment as compared to 28 weeks with gemcitabine; doubling of the one-year survival rate – 36% with our treatment vs. 18% with gemcitabine; tumor volume was reduced 25-50% in 4 of the 14 treated patients and remained stable in the remaining patients; no serious drug-related side effects with the encapsulated cell/ifosfamide treatment whereas serious and very serious side effects were reported with gemcitabine; the lack of serious side effects using our treatment is probably related to the use of “lower than normal” doses of ifosfamide; limited side effects and reduced cancer pain intensity led to a generally increased ‘quality of life” for the majority of patients. In a “worst case” scenario, some clinical benefit was seen in 50% of patients and in a “best case” scenario, this number increased to 71%; none of the patients who experienced a clinical benefit required and increase in their pain medication.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

India's First Upright Proton Therapy System Unveiled

A Leap Forward in Cancer Care: Proton Therapy Revolution Dang, just when you think you've heard it all in cancer treatment, Fortis Healthcare drops a bombshell: India’s first upright proton therapy system. Boom! This isn't your run-of-the-mill radiation treatment we're talking about here. This is the futuristic flair of the MEVION S250-FIT™, featuring upright...

Austin PostalAnnex Changes Hands After 19 Years

A Seamless Transition in Austin's PostalAnnex Legacy You know when a business digs its roots deep, becoming more than just a place but a part of the community fabric? That's what’s playing out at the PostalAnnex on W Parmer Lane, Austin. After nearly two decades, this battered yet steadfast hub of office and shipping services is swapping hands, all in the name of...

Mandeville Pests: Health Dangers Lurking at Home

Pest Trouble Brewing in Mandeville: A Health Alert There’s a storm brewing in Mandeville, Louisiana, and it's not the kind you can see rolling in on the horizon. We're talking about those sneaky pests going unnoticed in our homes. Folks, these pests aren't just a nuisance; they're ticking time bombs for public health. Take it from J&J Exterminating, who know a thing or...

Webinar Highlights Workforce Skills and AI Tools

The Shift Towards Skills-Based Talent Development The labor market's in a whirl, folks. Employers are scrambling to adapt to rapid changes, chasing after 'skills intelligence' like it's going out of style. On September 24, University of Phoenix, with its band of partners including Jobs for the Future and Skillmore™, will dig into this very topic. This upcoming webinar...

Strategic Hire: Whisenhunt Joins FlexScreen & RiteScreen

Shaking Up the Window Screens Biz If you've been grinding in the window and door game, you know it's not an industry with a lot of buzz, but here comes a shot of caffeine. FlexScreen and RiteScreen just snagged David Whisenhunt to rev up their sales machine. Who's David Whisenhunt? Well, he's no rookie. With over two decades deep in the fenestration field, Whisenhunt...

Nashville Benefit Concert Supports Animal Rescue Mission

Country Tunes and Compassion Unite for Rescue Efforts There's something electric about a community banding together, especially when it's through the warmth of country music and the noble mission of animal rescue. Animal Rescue Corps (ARC), meeting ground for art and heart, is turning the Nashville Palace into a sanctuary not just for music, but for hope. They've got...

Stoke Space Raises $1B; XTEND AI Hits NYSE

A Billion-Dollar Boost for Stoke Space Ever catch wind of a company hauling in a cool billion and shrug it off? Me neither. Stoke Space Technologies just locked down $1 billion in Series E funding. This ain't some pocket change—the kind of dough you need when you're eyeing stars and plotting orbital voyages. They're gearing up for a 2027 mission with their Nova...

Verdafero Gains Ground in Sustainable Hospitality

Verdafero's Latest Milestone: A Broader Environmental Reach It’s a day like today that makes you pause and realize that businesses in the hospitality space aren’t just about fluff and fancy lobbies anymore. They've got a new wave of responsibilities, especially with the globe pretty much on fire, literally and figuratively. Verdafero, a name not new to function and...

Drunk Angel Celebrates First Year in Crystal Jewelry

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

Everpure Surges into the S&P 500: A Milestone Move

Big Leagues Beckon: Everpure Enters the S&P 500 Another day, another dollar, but today ain't just any day for Everpure. They’re stepping up from the minor leagues and grabbing their spot in the illustrious S&P 500 lineup. We're talking about a milestone that every company dreams of, but few achieve—this ain't your regular Tuesday headline. Stock Market's Stamp of...